Zevra Therapeutics, Inc. (ZVRA)
Automate Your Wheel Strategy on ZVRA
With Tiblio's Option Bot, you can configure your own wheel strategy including ZVRA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ZVRA
- Rev/Share 1.1321
- Book/Share 2.14
- PB 4.4136
- Debt/Equity 0.5312
- CurrentRatio 7.8502
- ROIC -0.1223
- MktCap 530196020.0
- FreeCF/Share -0.8493
- PFCF -11.3957
- PE 195.6906
- Debt/Assets 0.243
- DivYield 0
- ROE 0.0395
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 2
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | ZVRA | H.C. Wainwright | -- | Buy | -- | $26 | July 2, 2025 |
| Resumed | ZVRA | Cantor Fitzgerald | -- | Overweight | -- | $25 | Jan. 8, 2025 |
| Initiation | ZVRA | Guggenheim | -- | Buy | -- | $20 | Oct. 7, 2024 |
| Initiation | ZVRA | JMP Securities | -- | Mkt Outperform | -- | $17 | Sept. 24, 2024 |
| Reiterated | ZVRA | Maxim Group | -- | Buy | $18 | $25 | Sept. 24, 2024 |
News
Zevra Therapeutics (ZVRA) Reports Q2 Loss, Tops Revenue Estimates (Revised)
Published: August 15, 2025 by: Zacks Investment Research
Sentiment: Negative
Zevra Therapeutics (ZVRA) came out with a quarterly earnings of $1.21 per share versus the Zacks Consensus Estimate of $2.19. This compares to a loss of $0.48 per share a year ago.
Read More
3 Biotech Stocks Likely to Outpace Q2 Earnings Estimates
Published: August 11, 2025 by: Zacks Investment Research
Sentiment: Positive
Zevra, Inovio and Journey Medical are set for potential earnings beat this week, backed by strong products and positive ESP scores.
Read More
What Makes Zevra Therapeutics (ZVRA) a Good Fit for 'Trend Investing'
Published: August 08, 2025 by: Zacks Investment Research
Sentiment: Positive
Zevra Therapeutics (ZVRA) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Read More
Zevra Therapeutics (ZVRA) Reports Next Week: Wall Street Expects Earnings Growth
Published: August 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Zevra Therapeutics (ZVRA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Does Zevra Therapeutics (ZVRA) Have the Potential to Rally 117.11% as Wall Street Analysts Expect?
Published: July 31, 2025 by: Zacks Investment Research
Sentiment: Positive
The mean of analysts' price targets for Zevra Therapeutics (ZVRA) points to an 117.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Read More
Are You Looking for a Top Momentum Pick? Why Zevra Therapeutics (ZVRA) is a Great Choice
Published: July 16, 2025 by: Zacks Investment Research
Sentiment: Positive
Does Zevra Therapeutics (ZVRA) have what it takes to be a top stock pick for momentum investors? Let's find out.
Read More
5 Small Drug Stocks to Buy Amid Trump's New Tariff Threats
Published: July 16, 2025 by: Zacks Investment Research
Sentiment: Positive
Innovation is at its peak in the Zacks Medical-Drugs industry. CPRX, ZVRA, TBPH, ALDX and LRMR may prove to be good additions to one's portfolio.
Read More
Wall Street Analysts Predict an 86.55% Upside in Zevra Therapeutics (ZVRA): Here's What You Should Know
Published: July 15, 2025 by: Zacks Investment Research
Sentiment: Positive
The average of price targets set by Wall Street analysts indicates a potential upside of 86.6% in Zevra Therapeutics (ZVRA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Read More
Here's Why 'Trend' Investors Would Love Betting on Zevra Therapeutics (ZVRA)
Published: July 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Zevra Therapeutics (ZVRA) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Read More
Zevra Therapeutics (ZVRA) Moves 5.1% Higher: Will This Strength Last?
Published: July 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Zevra Therapeutics (ZVRA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Read More
Zevra Therapeutics (ZVRA) Moves 5.1% Higher: Will This Strength Last?
Published: July 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Zevra Therapeutics (ZVRA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Read More
All Three Leading Proxy Advisory Firms – ISS, Glass Lewis, and Egan-Jones – Recommend Zevra Stockholders Vote FOR the Company's Director Nominees
Published: May 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
ISS, Glass Lewis, and Egan-Jones Unanimously Conclude Mangless Has Not Made a Compelling Case for Change Board and Management Urge Stockholders to Follow Proxy Advisors' Recommendation and Vote “FOR” Wendy L. Dixon, Ph.D.
Read More
Zevra Therapeutics Announces Details for Q1 2025 Financial Results Call
Published: May 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
Company will host conference call at 4:30 p.m. ET on Tuesday, May 13, 2025 Company will host conference call at 4:30 p.m. ET on Tuesday, May 13, 2025
Read More
Zevra to Participate at Upcoming Investor Conferences
Published: February 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
CELEBRATION, Fla., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that members of Zevra's executive leadership team will participate at the following March events:
Read More
About Zevra Therapeutics, Inc. (ZVRA)
- IPO Date 2015-04-16
- Website https://zevra.com
- Industry Biotechnology
- CEO Neil F. McFarlane
- Employees 59